Please assess the completion status of the following clinical trial:

Trial Title: Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes.~* Have been taking insulin glargine at a dose of ≥20 units/day for at least 3 months before entering the study.~Have been taking insulin glargine alone or in combination with one of the following for at least 3 months before entering the study:~1. metformin (stable dose for 6 weeks)~2. pioglitazone (stable dose for 6 weeks)~3. a combination of metformin and pioglitazone (stable dose for 6 weeks)~   * Have HbA1C between 7.1% and 10.5%, inclusive.~  * Have a body mass index (BMI) ≤45 kg/m2.~  * Have a history of stable body weight (not varying by \>5% for at least 3 months prior to screening).~Exclusion Criteria:~* Have taken medications to lower blood sugar other than insulin glargine, pioglitazone, or metformin in the 3 months before entering the study for more than a 1-week period, or within 1 week of entering the study.~* Have had more than one episode of major (severe) hypoglycemia in the 6 months before entering the study.~* Are pregnant or intend to become pregnant during the study or are sexually active women not actively practicing birth control.~* Women who are breastfeeding.~* Have any significant diseases of the blood, heart, kidney, gastrointestinal system, or other significant diseases such as cancer.~* Have had a kidney transplant or are currently on kidney dialysis.~* Have a cancer that's never been treated, that's currently being treated, or that was diagnosed within the last 5 years.~* Have had a bad reaction to exenatide in the past or have a condition that is not recommended to be exposed to exenatide or any of exenatide's other ingredients.~* Have used a drug for weight loss in the 3 months before entering the study for more than a 1-week period, or within 1 month of entering the study.~* Are currently on a weight-loss program or have been on one within 3 months of entering the study.~* Have had a blood transfusion or severe blood loss within 3 months of entering the study.~* Are taking systemic glucocorticoids or have received systemic glucocorticoids within 8 weeks of entering the study.~* Have an irregular sleep cycle (for example, sleeping during the day and working during the night).~* Have a history of pancreatitis.~* Have received treatment with an experimental drug within 30 days of entering the study.~* If on metformin, have a condition that is not recommended to be exposed to metformin, or any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis.~* If on metformin, have had a radiologic contrast study performed within 48 hours of entering the study.~* If on pioglitazone, have a condition that is not recommended to be exposed to pioglitazone, including congestive heart failure, or are taking pioglitazone at a dose that is not approved for use with insulin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).